Brilliant Violet 421TM anti-mouse CD335 (NKp46) [29A1.4] and 2 more items

BioLegend Inc. has been awarded contract A207_PO-0401614-V3 by the University of Virginia, an institution of higher education located in Virginia. The contract was executed on June 20, 2026. The contract calls for the delivery of specialized research reagents consisting of three monoclonal antibody products for laboratory use, all to be delivered to the buyer. These products include Brilliant Violet 421 anti-mouse CD335 (NKp46) clone 29A1.4, Allophycocyanin anti-mouse CD304 (Neuropilin-1) clone 3E12, and Brilliant Violet 421 anti-mouse CD19 clone 6D5.

The line items are structured with unit pricing, though specific contract value, annual value, cumulative value, and period of performance information are not populated in the available documentation. All three monoclonal antibody products are measured and priced on a per-unit basis. These reagents are commonly utilized in flow cytometry applications and immunological research protocols within academic laboratory settings. The contract represents a procurement of research-grade biological products by the University of Virginia from BioLegend Inc., a recognized supplier of immunological research reagents.